BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35794338)

  • 1. Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia.
    Grüninger PK; Uhl F; Herzog H; Gentile G; Andrade-Martinez M; Schmidt T; Han K; Morgens DW; Bassik MC; Cleary ML; Gorka O; Zeiser R; Groß O; Duque-Afonso J
    Cancer Gene Ther; 2022 Nov; 29(11):1751-1760. PubMed ID: 35794338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
    Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
    PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
    Weinberg MA
    Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.
    Simioni C; Cani A; Martelli AM; Zauli G; Tabellini G; McCubrey J; Capitani S; Neri LM
    Oncotarget; 2014 Oct; 5(20):10034-47. PubMed ID: 25296981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
    Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
    Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
    Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
    Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.
    Simioni C; Ultimo S; Martelli AM; Zauli G; Milani D; McCubrey JA; Capitani S; Neri LM
    Oncotarget; 2016 Nov; 7(48):79842-79853. PubMed ID: 27821800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia.
    Evangelisti C; Chiarini F; Cappellini A; Paganelli F; Fini M; Santi S; Martelli AM; Neri LM; Evangelisti C
    J Cell Physiol; 2020 Jun; 235(6):5413-5428. PubMed ID: 31904116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem Cells, and Therapeutic Targets.
    Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
    Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
    Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph
    Wu JH; Shi FF; Gong YP; Shi R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2017 Mar; 48(2):216-220. PubMed ID: 28612529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).
    Ehm P; Grottke A; Bettin B; Jücker M
    Cell Signal; 2022 May; 93():110301. PubMed ID: 35259456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat Stress-Induced PI3K/mTORC2-Dependent AKT Signaling Is a Central Mediator of Hepatocellular Carcinoma Survival to Thermal Ablation Induced Heat Stress.
    Thompson SM; Callstrom MR; Jondal DE; Butters KA; Knudsen BE; Anderson JL; Lien KR; Sutor SL; Lee JS; Thorgeirsson SS; Grande JP; Roberts LR; Woodrum DA
    PLoS One; 2016; 11(9):e0162634. PubMed ID: 27611696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.
    Neri LM; Cani A; Martelli AM; Simioni C; Junghanss C; Tabellini G; Ricci F; Tazzari PL; Pagliaro P; McCubrey JA; Capitani S
    Leukemia; 2014 Apr; 28(4):739-48. PubMed ID: 23892718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NOP14-mediated ribosome biogenesis is required for mTORC2 activation and predicts rapamycin sensitivity.
    Yan X; Kuang BH; Ma S; Wang R; Lin J; Zeng YX; Xie X; Feng L
    J Biol Chem; 2024 Mar; 300(3):105681. PubMed ID: 38272224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The depletion of Circ-PRKDC enhances autophagy and apoptosis in T-cell acute lymphoblastic leukemia via microRNA-653-5p/Reelin mediation of the PI3K/AKT/mTOR signaling pathway.
    Ling Z; Fang ZG; Wu JY; Liu JJ
    Kaohsiung J Med Sci; 2021 May; 37(5):392-401. PubMed ID: 33615686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
    Razmara M; Monazzam A; Skogseid B
    Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.